These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 29949683)
1. Impact of Drug Exposure Definitions on Observed Associations in Pharmacoepidemiology Research. Eskin M; Eurich DT; Simpson SH J Popul Ther Clin Pharmacol; 2018 Mar; 25(1):e39-e52. PubMed ID: 29949683 [TBL] [Abstract][Full Text] [Related]
2. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677 [TBL] [Abstract][Full Text] [Related]
4. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies? Palmaro A; Boucherie Q; Dupouy J; Micallef J; Lapeyre-Mestre M Pharmacoepidemiol Drug Saf; 2017 May; 26(5):544-553. PubMed ID: 28266748 [TBL] [Abstract][Full Text] [Related]
5. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Bowker SL; Majumdar SR; Veugelers P; Johnson JA Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869 [TBL] [Abstract][Full Text] [Related]
6. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708 [TBL] [Abstract][Full Text] [Related]
7. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Kowall B; Rathmann W; Kostev K Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes. Eskin M; Simpson SH; Eurich DT Can J Diabetes; 2019 Jul; 43(5):322-328. PubMed ID: 30782471 [TBL] [Abstract][Full Text] [Related]
9. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Tseng CH Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555 [TBL] [Abstract][Full Text] [Related]
10. Metformin use and survival after colorectal cancer: A population-based cohort study. Mc Menamin ÚC; Murray LJ; Hughes CM; Cardwell CR Int J Cancer; 2016 Jan; 138(2):369-79. PubMed ID: 26331456 [TBL] [Abstract][Full Text] [Related]
11. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892 [TBL] [Abstract][Full Text] [Related]
12. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Gulliford M; Latinovic R Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756 [TBL] [Abstract][Full Text] [Related]
13. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Kim YI; Kim SY; Cho SJ; Park JH; Choi IJ; Lee YJ; Lee EK; Kook MC; Kim CG; Ryu KW; Kim YW Aliment Pharmacol Ther; 2014 Apr; 39(8):854-63. PubMed ID: 24612291 [TBL] [Abstract][Full Text] [Related]
14. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Johnson JA; Majumdar SR; Simpson SH; Toth EL Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968 [TBL] [Abstract][Full Text] [Related]
15. Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan. Lu CH; Chung CH; Lee CH; Hsieh CH; Hung YJ; Lin FH; Tsao CH; Hsieh PS; Chien WC PLoS One; 2018; 13(1):e0191242. PubMed ID: 29385156 [TBL] [Abstract][Full Text] [Related]
16. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Ou HT; Chang KC; Li CY; Wu JS Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742 [TBL] [Abstract][Full Text] [Related]
17. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. Cheng YY; Leu HB; Chen TJ; Chen CL; Kuo CH; Lee SD; Kao CL J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e99-105. PubMed ID: 24119365 [TBL] [Abstract][Full Text] [Related]
18. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Kowall B; Stang A; Rathmann W; Kostev K Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313 [TBL] [Abstract][Full Text] [Related]
19. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Suissa S; Moodie EE; Dell'Aniello S Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):459-468. PubMed ID: 27610604 [TBL] [Abstract][Full Text] [Related]
20. A probabilistic bias analysis for misclassified categorical exposures, with application to oral anti-hyperglycaemic drugs. Arfè A; Nicotra F; Ghirardi A; Simonetti M; Lapi F; Sturkenboom M; Corrao G Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1443-1450. PubMed ID: 27594547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]